Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
INDIANAPOLIS , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated with the human
View HTML
Toggle Summary Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
NEW YORK , June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated with the human
View HTML
Toggle Summary Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1 Trials in 2H16 While Also Advancing Additional CpAM Compounds— BARCELONA, Spain and NEW YORK , April
View HTML
Toggle Summary Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
BARCELONA, Spain and NEW YORK , March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B
View HTML
Toggle Summary Assembly Biosciences to Webcast Upcoming Investor Conferences
INDIANAPOLIS , Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection,
View HTML
Toggle Summary Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel® Technology Achieves Targeted Delivery to the Lower GI Tract
Phase I Scintigraphy Data Confirms Gemicel Can Deliver Therapeutics to Targeted Regions of the Lower GI Tract Favorable for Microbiome Therapies
View HTML
Toggle Summary Assembly Biosciences Expands Senior Leadership Team
INDIANAPOLIS , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the
View HTML
Toggle Summary Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors
INDIANAPOLIS , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced the appointment of Alan J.
View HTML
Toggle Summary Assembly Biosciences to Present at Jefferies Microbiome Summit
INDIANAPOLIS , Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participate in the Jefferies
View HTML
Toggle Summary Clinical Study Shows Assembly Biosciences' Oral Gemicel® Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver Selected Bacteria Strains to the GI Tract that Recapitulate the Effects of FMT as Treatment for CDI— NEW
View HTML